anti-clotting drugs

A new, genetically engineered drug that counteracts non-coumadin, anti-clotting agents has passed some safety and efficacy tests. If future research confirms the results of a recent study, it may well remove one of the major drawbacks to the use of these newer anti-clotting agents.